Month: May 2025

Lochem, 20 May 2025 Update on and end of share buy-back programme ForFarmers  ForFarmers N.V. (ForFarmers) has repurchased 37,881 shares on 19 May 2025. The shares were repurchased at an average price of €4.36 per share, for a total amount of €165,260. These repurchases were made in accordance with the authorisation granted by the ForFarmers Annual General Meeting of Shareholders on 17 April 2025. The authorisation concerns the buy-back of shares for ForFarmers to fulfil its obligations arising from (depositary receipts for) share-related incentive schemes. It concerns a maximum of 400,000 shares, for a maximum amount of €2,400,000.  The total number of shares that has been repurchased to date according to this programme is 400,000 shares, for a total amount of €1,675,903. ForFarmers has herewith completed the share buy-back programme. More...

PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 1.8 MILLION PRIVATE PLACEMENT Paris, May 20, 2025, 8am AB Science S.A. (the “Company” or “AB Science”, Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 1.8 million subscribed by a limited number of investors (the “Private Placement”). The Private Placement is not subject to a prospectus requiring an approval from the French Financial Market Authority (Autorité des Marchés Financiers – the “AMF”). Use of proceeds The Company intends to use the net proceeds of the Private Placement to finance its ongoing activities, with a focus on the clinical development of the AB8939 program. Terms and conditions of the Private Placement The Private Placement, for a total amount of EUR 1.8 million (including...

Allschwil, Switzerland, May 20, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its antibiotic Zevtera® (ceftobiprole medocaril for injection) is now commercially available in the United States through Basilea’s partner Innoviva Specialty Therapeutics, Inc., a wholly owned subsidiary of Innoviva, Inc. (NASDAQ: INVA). Zevtera is used in hospitals for the treatment of bacterial infections, such as those caused by Staphylococcus aureus bacteria, including methicillin-resistant strains (MRSA). It is the only advanced-generation cephalosporin approved by the United States Food and Drug Administration (FDA) for the treatment of adult patients with Staphylococcus aureus bacteremia (SAB),...

The net asset value (NAV) of EfTEN United Property Fund units was 11,53 euros at the end of April, increasing by 1,6% per month. The fund earned a net profit of 449 thousand euros in April and a net profit of 1,15 million euros during the four months of 2025 (last year at the same time 331 thousand euros). If the fund’s investment in EfTEN Real Estate Fund AS shares were recorded on the basis of its net asset value, the NAV of EfTEN United Property Fund would be 11,58 euros, increasing by 1,4% per month.  In April, the fund received the biggest profit (274 thousand euros) from its investment in the development company Invego Uus-Järveküla OÜ. During the month the last terraced houses of the development’s second stage were transferred to clients in the Uus-Järveküla (real right agreements were concluded), from which the company earned...

Global leaders in sustainable agricultural innovation to develop biological solutions to reduce food waste Ghent, BELGIUM, and Philadelphia, USA, May 20, 2025 (GLOBE NEWSWIRE) — Press release Ghent, BELGIUM, and Philadelphia, USA – 20 May 2025, 07.00 CEST – An estimated 14 percent of produce is lost between harvest and retail*, in part due to spoilage from mold and rot. To help address this global challenge, Biotalys (Euronext – BTLS), an agricultural technology (AgTech) company developing protein-based biocontrol solutions for sustainable crop protection, and AgroFresh Solutions, Inc., a global leader in post-harvest solutions for fresh produce, today announced a new collaboration to develop and commercialize sustainable biological fungicides for post-harvest use. Fungicides are already essential to protect fresh produce...

The collaboration will provide GF with access to A*STAR’s state-of-the-art R&D facilities, capabilities and technical support for technology development and workforce skills enhancement in advanced packaging SINGAPORE, May 19, 2025 (GLOBE NEWSWIRE) — GlobalFoundries (Nasdaq: GFS) (GF) today announced plans to expand its capabilities in advanced packaging through a new Memorandum of Understanding (MOU) signed with the Agency for Science, Technology and Research (A*STAR), Singapore’s lead public sector research and development (R&D) agency. Advanced packaging has become a key R&D priority for the semiconductor industry amid growing demand for artificial intelligence (AI) and other data-intensive applications ranging from high performance data computing and datacenters to 5G / 6G communication and more. To meet these...

BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 2,000,000 units, with each unit consisting of one ordinary share (or pre-funded warrant in lieu thereof), one Series A warrant to purchase one ordinary share, and one Series B warrant to purchase one ordinary share for gross proceeds of approximately $4.0 million. Each unit is being sold at an effective offering price of $2.00 per unit. Each Series A warrant will be immediately exercisable at an exercise price of $2.00 per share and will expire five years from the date of issuance. Each Series B warrant will be immediately exercisable at an exercise price...

HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) — PrimeEnergy Resources Corporation (NASDAQ: PNRG) today announced first quarter 2025 results, with continued growth in oil and gas production supporting a 16.4% increase in revenue year-over-year. While earnings per share declined compared to Q1 2024, the Company highlighted significant shareholder returns and operational momentum. Key Highlights – Q1 2025 vs Q1 2024• Revenue: $50.1 million ↑ 16.4% • Oil Production: 457,000 barrels ↑ 6.0% • Natural Gas Production: 2.39 Bcf ↑ 106.6% • NGL Production: 454,000 barrels ↑ 120.4% • Net Income: $9.1 million ↓ 19.3% • Diluted EPS: $3.72 ↓ 15.7% • Share Buyback 2025: 47,970 shares repurchased at a cost of $9.17 million Since initiating its share repurchase program, PrimeEnergy has returned a total of $112.6 million to shareholders through stock repurchases....

Collaboration with Intel Foundry opens access to a proven SLT and Burn-In test ecosystem and test engineering, accelerating time-to-market for fabless customers SINGAPORE, May 20, 2025 (GLOBE NEWSWIRE) — AEM Holdings Ltd. (SGX: AWX, Reuters: AEM.SI, Bloomberg: AEM:SP) today announced it is working with Intel Foundry to expand access to their established System-Level Test (SLT) and Burn-In capabilities, tailored for advanced computing devices, to Intel Foundry’s customer base. Built on decades of collaboration, AEM and Intel Foundry have developed one of the most extensive and mature SLT and Burn-In ecosystems. As chips grow in complexity, particularly in high-performance computing (HPC) and artificial intelligence (AI) applications, the need for Burn-In and SLT test solutions has become more critical than ever, to ensure test coverage...